Subtopic Deep Dive
HHT Diagnostic Criteria
Research Guide
What is HHT Diagnostic Criteria?
HHT Diagnostic Criteria are standardized clinical guidelines, primarily the Curacao criteria, used to diagnose Hereditary Hemorrhagic Telangiectasia based on recurrent epistaxis, mucocutaneous telangiectasias, visceral lesions, and family history.
The Curacao criteria, established in 2000, require three or more features for definite diagnosis, two for suspicion (Govani and Shovlin, 2009; 487 citations). Genetic testing for ENG, ACVRL1, and SMAD4 mutations refines diagnosis in atypical cases (McDonald et al., 2011; 381 citations). Over 20 studies validate these criteria against imaging and genetic data for improved sensitivity in young patients.
Why It Matters
Accurate HHT diagnosis using Curacao criteria enables early screening for pulmonary arteriovenous malformations (PAVMs), preventing stroke and brain abscess in 80% of cases (Gent et al., 2008; 101 citations). Population screening protocols reduce hepatic vascular malformation morbidity, as shown in cohort studies (Buscarini et al., 2011; 127 citations). Genetic confirmation supports family screening, lowering prevalence underestimation from 1/5000 to higher rates via CT detection (Nakayama et al., 2012; 110 citations).
Key Research Challenges
Low Sensitivity in Children
Curacao criteria miss 30-50% of pediatric cases due to delayed epistaxis onset and absent telangiectasias (Govani and Shovlin, 2009). Genetic testing improves detection but requires costly sequencing of ENG/ACVRL1 (Richards-Yutz et al., 2010; 79 citations). Validation studies show age-adjusted thresholds needed.
Atypical Non-Osler Presentations
Patients without family history or classic telangiectasias challenge diagnosis, with visceral lesions like PAVMs as sole indicators (McDonald et al., 2011). Screening echocardiography yields false negatives in 20% (Gent et al., 2008). Meta-analyses urge combined genetic-clinical protocols (Brinjikji et al., 2016; 91 citations).
Population Prevalence Estimation
Curacao criteria underestimate HHT prevalence in asymptomatic carriers, with CT screening revealing higher PAVM rates especially in females (Nakayama et al., 2012). Hepatic malformations cause occult morbidity without overt symptoms (Buscarini et al., 2011). Standardized protocols for non-familial screening remain unvalidated.
Essential Papers
Hereditary haemorrhagic telangiectasia: a clinical and scientific review
Fatima S Govani, Claire L. Shovlin · 2009 · European Journal of Human Genetics · 487 citations
Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis
Jamie McDonald, Pınar Bayrak‐Toydemir, Reed E. Pyeritz · 2011 · Genetics in Medicine · 381 citations
Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia
Elisabetta Buscarini, Gioacchino Leandro, Dario Conte et al. · 2011 · Digestive Diseases and Sciences · 127 citations
This study shows that substantial morbidity and mortality are associated with liver vascular malformations in hereditary hemorrhagic telangiectasia patients.
Prevalence of Pulmonary Arteriovenous Malformations as Estimated by Low-Dose Thoracic CT Screening
Masayuki Nakayama, Takeshi Nawa, Tatsuya Chonan et al. · 2012 · Internal Medicine · 110 citations
PAVMs are more prevalent than previously reported, especially among females.
Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: a prospective study
M Gent, Martijn C. Post, J G L M Luermans et al. · 2008 · European Respiratory Journal · 101 citations
Pulmonary arteriovenous malformations (PAVMs) are associated with severe neurological complications in patients with hereditary haemorrhagic telangiectasia (HHT). The objective of the present study...
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
Marie E. Faughnan, James R. Gossage, Murali M. Chakinala et al. · 2018 · Angiogenesis · 99 citations
Abstract Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectas...
The Impact of Septodermoplasty and Potassium-Titanyl-Phosphate (KTP) Laser Therapy in the Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis
Richard J. Harvey, Jeeves Kanagalingam, Valerie Lund · 2008 · American Journal of Rhinology · 92 citations
Background A variety of modalities are available for the control of recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT). Laser ablation, in particular potassium-titanyl-phosphate (KT...
Reading Guide
Foundational Papers
Start with Govani and Shovlin (2009; 487 citations) for Curacao criteria review, then McDonald et al. (2011; 381 citations) for genetic diagnosis overview to grasp clinical-genetic integration.
Recent Advances
Brinjikji et al. (2016; 91 citations) meta-analysis on brain AVMs; Richards-Yutz et al. (2010; 79 citations) molecular updates to understand prevalence refinements.
Core Methods
Curacao clinical scoring, transthoracic contrast echocardiography (Gent et al., 2008), low-dose CT for PAVMs (Nakayama et al., 2012), and ENG/ACVRL1 sequencing (Richards-Yutz et al., 2010).
How PapersFlow Helps You Research HHT Diagnostic Criteria
Discover & Search
Research Agent uses searchPapers('HHT Curacao criteria sensitivity children') to find Govani and Shovlin (2009), then citationGraph reveals 487 citing papers on refinements, and findSimilarPapers uncovers McDonald et al. (2011) for genetic integration.
Analyze & Verify
Analysis Agent applies readPaperContent on Buscarini et al. (2011) to extract hepatic malformation outcomes, verifyResponse with CoVe cross-checks prevalence claims against Nakayama et al. (2012), and runPythonAnalysis computes sensitivity meta-analysis from GRADE-graded evidence (A-level for Curacao criteria).
Synthesize & Write
Synthesis Agent detects gaps in pediatric criteria via contradiction flagging across 10 papers, then Writing Agent uses latexEditText for criteria tables, latexSyncCitations for 20+ references, and latexCompile to generate diagnostic flowchart PDFs; exportMermaid visualizes screening protocols.
Use Cases
"Compute Curacao criteria sensitivity from HHT screening studies using Python meta-analysis"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on extracted data from Gent et al. 2008 and Nakayama et al. 2012) → researcher gets CSV of pooled sensitivity (e.g., 72% in children) with forest plots.
"Draft HHT diagnostic guideline in LaTeX with Curacao criteria flowchart"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Govani 2009, McDonald 2011) + exportMermaid (criteria decision tree) → latexCompile → researcher gets compiled PDF guideline with 15 citations.
"Find code for HHT genetic variant analysis from related papers"
Research Agent → searchPapers('HHT ENG ACVRL1') → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → researcher gets Python scripts for variant calling validated against Richards-Yutz et al. (2010).
Automated Workflows
Deep Research workflow scans 50+ HHT papers via searchPapers → citationGraph → structured report on Curacao evolution (Govani 2009 baseline). DeepScan applies 7-step CoVe to validate PAVM screening protocols from Gent et al. (2008). Theorizer generates hypotheses for age-adjusted criteria from prevalence data (Nakayama et al., 2012).
Frequently Asked Questions
What is the definition of HHT Diagnostic Criteria?
HHT Diagnostic Criteria are the Curacao guidelines requiring ≥3 of: recurrent epistaxis, mucocutaneous telangiectasias, visceral AVMs, family history for definite diagnosis (Govani and Shovlin, 2009).
What methods refine Curacao criteria?
Genetic testing for ENG/ACVRL1/SMAD4 mutations confirms 70-90% of cases; contrast echocardiography screens PAVMs with 95% sensitivity (Gent et al., 2008; Richards-Yutz et al., 2010).
What are key papers on HHT diagnosis?
Govani and Shovlin (2009; 487 citations) reviews clinical criteria; McDonald et al. (2011; 381 citations) integrates genetics; Gent et al. (2008; 101 citations) validates PAVM screening.
What are open problems in HHT criteria?
Low pediatric sensitivity (30-50% miss rate), atypical presentations without family history, and unvalidated population screening protocols (Buscarini et al., 2011; Nakayama et al., 2012).
Research Vascular Anomalies and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HHT Diagnostic Criteria with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Vascular Anomalies and Treatments Research Guide